Contents

U-M Fast Forward GI Innovation Fund

Taubman Institute Innovation Programs: Phenotyping in the Clinical Setting

American Diabetes Association Pathway to Stop Diabetes Initiator Award (INI)

American Diabetes Association Pathway to Stop Diabetes Accelerator Award (ACE)

American Diabetes Association Pathway to Stop Diabetes Visionary Award (VSN)

Prostate Cancer Foundation Request for Team Science Applications for 2018 PCF Challenge Award

2018 ASPIRE Breast Cancer Research Awards Program Request for Proposals

Call for Applications: Jacobs Foundation Research Fellowship Program

Craig H. Neilsen Foundation Psychosocial Research Studies and Demonstration Projects

Independent Grants for Learning & Change Track 2 - Call for Grant Applications Emerging Treatments and Preventative Care Strategies for Patients With Inflammatory Bowel Disease (IBD)

Independent Grants for Learning & Change Track 2 - Call for Grant Applications Advances in Adjuvant Treatment in Renal Cell Carcinoma (RCC)

Craig H. Neilsen Foundation Psychosocial Research Pilot Grants

National Hemophilia Foundation-Shire Clinical Fellowship Program

Independent Grants for Learning & Change Track 2 - Call for Grant Applications Understanding the Importance of Calcium and Vitamin D Supplementation for Aging Men

Independent Grants for Learning & Change Fellowship Request for Proposal: Rheumatology

Cystic Fibrosis Foundation Mental Health Coordinator Award

Craig H. Neilsen Foundation Psychosocial Research Postdoctoral Fellowships

Tuberous Sclerosis Alliance Postdoctoral Fellowships

Tuberous Sclerosis Alliance Research Grants

Orphan Disease Center and Loulou Foundation 2018 CDKL5 Program of Excellence Pilot Grant Program

NINDS Center for SUDEP Research Pilot

Call for Proposals: Oxalosis & Hyperoxaluria Foundation Global Registry Initiative

ZOLL Foundation Grants Program

Call for Grant Applications: Oral Health

Call for Nominations: 2018 Switzer Prize
Please note that a faculty member’s research administrator will serve as the liaison on all aspects of the internal application process. If you are unsure of whom to talk to, your department contact can be found at the following link. If you pursue any grant opportunity featured in this report, please contact your research administrator first to formulate a submission plan and timeline.

The UMHS Corporate and Foundation Relations team can assist in this process, including providing direct communication with the funding entity to obtain guidance on project appeal/applicability to the funder, provide examples of previously funded UM proposals, and answer general faculty questions.

Internal Funding Opportunity

[Please note that this is a reposting of a grant first posted in the January 15-19, 2018 grants report]

Grantor: U-M Fast Forward GI Innovation Fund

Grant Opportunity: Research Grants

Keyword: Chronic Diseases; Devices & Robotics; Public Health; Research Grant

Award Amount: $100,000

Deadline: March 16, 2018

U-M Fast Forward GI Innovation Fund

https://innovation.medicine.umich.edu/internal-funding/gi-innovation-fund/

The U-M Fast Forward Gastrointestinal (GI) Innovation Fund is a three-year, $500,000+ fund supported by a donation from entrepreneur alumna Mary Petrovich and matched by the U-M Medical School’s Department of Internal Medicine and its Division of Gastroenterology, as well as the College of Engineering, where Ms. Petrovich received her undergraduate degree. The three-year program, which began in 2016, targets discovery and development of future technologies to help patients suffering from gastrointestinal disease.
The U-M Fast Forward GI Innovation Fund supports early-stage research and commercialization activities such as those related to technology validation and establishing proof-of-concept, including pilot funding support for preliminary studies or development activities that will lead to broader GI product applications. Importantly the fund seeks to engage interdisciplinary teams of researchers that leverage ideas and technologies across medicine, engineering, public health, and other key units engaged in biomedical research.

The FFMI team has assembled a GI Fund Advisory Board of faculty, industry, and commercialization experts who review proposals and provide mentorship for the funded teams. The award ranges are estimates and actual funding levels will be project-specific.

Tier I Awards – $25-$50K – fund projects that address a discrete milestone that is critical to the advancement of research to the point of product development.

Tier II Awards – $75-$100K – fund projects with specific milestones for proof-of-concept and later-stage translational studies

Proposal Submissions Due March 30, 2018

Note: A pre-submission application and meeting with FFMI staff is REQUIRED and must be completed on or before March 16, 2018

Internal Funding Opportunity

Grantor: A. Alfred Taubman Medical Research Institute
Grant Opportunity: Research Grants
Keyword: Basic Science; Research Grant
Award Amount: Not Specified
Deadline: Rolling

Taubman Institute Innovation Programs: Phenotyping in the Clinical Setting

http://www.taubmaninstitute.org/science/taubman-institute-innovation-program/

The Taubman Institute is seeking to support new or existing teams of scientists to develop novel and impactful approaches to integrate their research programs into the clinic setting. The goal is to perform systematic, multiscale phenotyping to gain insights into individual variation in the susceptibility, progression, course, or outcomes of disease.

The institute will partner with investigators to support the development and implementation of their research programs. This will include, but not be limited to, development of a research plan,
identification of research partners within and external to U-M, infrastructure and database development, support for clinician and ancillary personnel in the clinic, clinical data collection, biological specimen collection, remote data collection, initiation of research plan, and data analysis.

Our goal is to make every patient a research subject, and to define the genetic, environmental, behavioral and other components of individuals that contribute to their distinct emergent property related to health and disease. The goal is to also utilize the data to stratified an individual in order apply interventions that lead to the prevention, improved treatment, or cure of disease.

The institute anticipates investing up to $2.5 million per year to support the funded projects.

What are the criteria for funding?

Impact on improving the lives of patients

Innovation in understanding the variability in onset or progression of disease, and reasons for differential response to treatment

Potential for future funding by the NIH or other external agencies

Potential for increased reimbursement for care by insurance companies, or cost savings to the medical system

Enhanced interactions with basic or other science disciplines (teams)

Letter of intent

Description of the proposed program

Who is going to work together and what will be their roles? Have you worked together in the past?

Where do you want to perform this work?

What infrastructure is needed to accomplish the goals?

Who will you need to partner with to succeed?

What are the present barriers to your success?

What are your plans for downstream funding?

Note: not all of these points must be addressed in the LOI. We seek to understand your vision for bringing science into the clinic. The main request here is for an outline of what you want to do and why it will be impactful.

There is no deadline. Letters of intent are accepted on a rolling basis, and should be submitted to managing director Grace Wu (glwu@umich.edu).

Questions?
We encourage questions. You may contact us with written questions through Grace Wu (glwu@umich.edu). We’re happy to meet with individuals or teams to discuss ideas.

Grantor: American Diabetes Association
Grant Opportunity: Career Development
Keyword: Basic Science; Career Development; Chronic Diseases; Diabetes; Diabetes Type – II; Health Policy & Research; Research Grant
Award Amount: $1,625,000
Deadline: July 2, 2018

American Diabetes Association Pathway to Stop Diabetes Initiator Award (INI)

https://professional.diabetes.org/meetings/pathway-stop-diabetes%C2%AE
Pathway to Stop Diabetes is a bold, innovative initiative designed to radically transform diabetes research.
Pathway seeks to bring new investigators and new perspectives to diabetes research. Supporting scientists with different backgrounds and experience is critical to achieving that objective. Pathway accepts nominations for exceptional investigators with medical and scientific backgrounds who propose innovative basic, clinical, translational, behavioral, epidemiological and health services research relevant to any type of diabetes, diabetes-related disease state or complication.
Description: This two-phased award is designed to support the transition of scientists from mentored training to independent research faculty.
Support: Awards provide two distinct phases of research support: Phase 1 provides up to two years of support for mentored training at a maximum of $100,000 per year (including 10% indirect costs), Phase 2 provides up to five years of support for independent research at a maximum of $325,000 per year (including 30% indirect costs). Maximum combined support for Phase 1 and Phase 2 is $1,625,000.
Deadline: July 2, 2018 for January 1, 2019 funding

Grantor: American Diabetes Association
Grant Opportunity: Career Development
Keyword: Basic Science; Career Development; Chronic Diseases; Diabetes; Diabetes Type – II; Health Policy & Research; Research Grant
Award Amount: $1,625,000
Deadline: July 2, 2018

American Diabetes Association Pathway to Stop Diabetes Accelerator Award (ACE)

https://professional.diabetes.org/meetings/pathway-stop-diabetes%C2%AE

Pathway to Stop Diabetes is a bold, innovative initiative designed to radically transform diabetes research.

Pathway seeks to bring new investigators and new perspectives to diabetes research. Supporting scientists with different backgrounds and experience is critical to achieving that objective. Pathway accepts nominations for exceptional investigators with medical and scientific backgrounds who propose innovative basic, clinical, translational, behavioral, epidemiological and health services research relevant to any type of diabetes, diabetes-related disease state or complication.

Description: This award is designed to support exceptional, independent early-career researchers who have distinguished themselves as promising investigators and are in the beginning stages of establishing successful, sustainable diabetes research programs.

Support: Awards provide five years of research support at a maximum of $325,000 per year (including 30% indirect costs), for a total of $1,625,000.

Deadline: July 2, 2018 for January 1, 2019 funding

Grantor: American Diabetes Association
Grant Opportunity: Career Development
Keyword: Basic Science; Career Development; Chronic Diseases; Diabetes; Diabetes Type – II; Health Policy & Research; Research Grant

American Diabetes Association Pathway to Stop Diabetes Visionary Award (VSN)

https://professional.diabetes.org/meetings/pathway-stop-diabetes%C2%AE

Pathway to Stop Diabetes is a bold, innovative initiative designed to radically transform diabetes research.

Pathway seeks to bring new investigators and new perspectives to diabetes research. Supporting scientists with different backgrounds and experience is critical to achieving that objective.
Pathway accepts nominations for exceptional investigators with medical and scientific backgrounds who propose innovative basic, clinical, translational, behavioral, epidemiological and health services research relevant to any type of diabetes, diabetes-related disease state or complication.

Description: Awards are designed to support established, experienced investigators with strong records of outstanding productivity in fields outside of diabetes who are interested in applying their considerable skills and expertise to diabetes research. These awards are highly competitive and intended to support particularly innovative and transformational ideas that have the potential to have an exceptional impact in diabetes.

Support: Awards provide two distinct phases of research support: Phase 1 provides up to three years of support at a maximum of $325,000 per year (including 30% indirect costs), Phase 2 provides up to two years of support at a maximum of $325,000 per year (including 30% indirect costs). Phase 2 is contingent upon demonstration of significant contributions to the field of diabetes research in Phase 1. Maximum combined support for Phase 1 and Phase 2 is $1,625,000.

Deadline: July 2, 2018 for January 1, 2019 funding

Grantor: Prostate Cancer Foundation
Grant Opportunity: Research Grants
Keyword: Basic Science; Cancer; Chronic Diseases; Immuno-oncology; Prostate Cancer; Research Grant
Award Amount: $1 Million
Deadline: April 23, 2018

Prostate Cancer Foundation Request for Team Science Applications for 2018 PCF Challenge Award

https://www.pcf.org/c/open-rfas/

The Prostate Cancer Foundation (PCF) is pleased to announce a Request for Team Science Applications for PCF Challenge Awards for investigations of metastatic, lethal prostate cancer. High risk, currently unfunded projects are most desired. We especially seek applications conducting research in VA hospitals where research directly affects veterans with advanced prostate cancer.

PCF Challenge Awards:
Composed of a team of at least three (3) investigators from non-profit academic research centers, including one young investigator.

Support large-scale research projects concerning metastatic, lethal prostate cancer over a duration of two years.

Provide up to a total of $1 million per team.

Cover only direct research costs and travel to the Annual PCF Scientific Retreat.

Research proposals in the following topic areas are preferred:

- Immunotherapy for the treatment of metastatic, lethal prostate cancer.
- Targeted radionuclide therapy for advanced prostate cancer.
- New systemic precision treatments for metastatic, lethal prostate cancer including those targeting the currently ‘undruggable’.
- First-in-field research on new targets for systemic treatment of metastatic, lethal prostate cancer.
- Mechanisms of resistance to current and investigational drugs targeting the androgen receptor and androgen axis, immune system, chemotherapy, and other targeted agents.
- Correlative research around either clinical trials of novel agents or strategies or standard of care.
- Developing or validating biomarkers that guide therapy in patients or further our understanding of the mechanisms by which therapies work.
- Tumor microenvironment signaling related to cancer progression including the immune component.
- New bioinformatics technologies for analysis of genomic data and big data of clinical outcomes.

Deadline: April 23, 2018, 3:00 pm, Eastern Daylight Time (EDT)

Grantor: Pfizer

Grant Opportunity: Research Grants

Keyword: Breast Cancer; Cancer; Chronic Diseases; Research Grant; Women’s Health

Award Amount: $666,666 (?)

Deadline: April 27, 2018

2018 ASPIRE Breast Cancer Research Awards Program Request for Proposals

https://www.aspireresearch.org/onc/index.html

The ASPIRE Breast Cancer Research Awards Program underscores Pfizer’s commitment to supporting investigators in advancing their academic research in the field of breast cancer.
Mission: The mission of the ASPIRE Awards program is to support clinical research in the field of breast cancer through a competitive grants program.

Background: This program is to support continuous medical research to maximize the available therapies by improving medical knowledge and clinical management of the disease.

Request for Proposals: Pfizer invites investigators to apply for the 2018 ASPIRE Breast Cancer Research Awards program through submission of innovative clinical research proposals designed to accomplish the mission of advancing knowledge of select Pfizer compounds in the treatment and disease management of breast cancer.

Scope of Research Areas

Pfizer is interested in supporting clinical studies in breast cancer, focusing in the following areas:

In hormone receptor positive (HR+) advanced breast cancer, safety and efficacy profile of palbociclib/hormone therapy given concurrently with radiation in patients with bone disease

In HER2- advanced breast cancer, safety and efficacy profile of talazoparib novel combination (except CDK4/6 inhibitors) in patients with HRD/DDR deficiency

In HER2- advanced breast cancer, safety and efficacy profile of gedatolisib plus talazoparib combination in appropriate patients

In early stage breast cancer setting, translational end point driven study to explore potential effect of gedatolisib on immune system in regard to PD-1, PD-L1, TILs, and other appropriate markers, with or without an immunotherapy agent

In addition, the following would be of interest: incorporation of a correlative/biomarker component into the proposed clinical study using paired biopsy samples, e.g pre- and post-treatment, liquid biopsy, or PK/PD biomarkers to explore potential mechanism of resistance or response, synergistic effect, and etc.

Available Awards: 2018 ASPIRE Breast Cancer Research Awards intend to fund 4 to 6 clinical studies within research scope, for a total of approximately 4 million US dollars. It is open to US investigators. Selection of research proposals will be performed by an independent external review panel of experts.

Stage 1 Application deadline: April 27, 2018 (by 11:59pm EST in the United States), NO EXCEPTIONS

Grantor: Jacobs Foundation

Grant Opportunity: Research Fellowship Program

Keyword: Neurological Disorders; Post-Doctoral Fellowship

Award Amount: $426,764
Call for Applications: Jacobs Foundation Research Fellowship Program

https://jacobsfoundation.org/en/activity/call-for-applications/

The Jacobs Foundation Research Fellowship Program is a globally competitive fellowship program for early and mid-career researchers aiming at improving the learning, development and living conditions of children and youth or contributing to one of the Jacobs Foundation’s thematic priorities. This includes, but is not limited to educational sciences, psychology, economics, sociology, family studies, media studies, political sciences, linguistics, neurosciences, and medical sciences.

Fellowships are awarded to the most highly talented and innovative young scholars and mid-career researchers. Funds from Jacobs Foundation Research Fellowships are awarded directly to the fellow’s institution and may be used over a three-year period by the fellow to partially cover the fellow’s salary and for any activity supporting the fellow’s research, such as assistant salaries, equipment, technical assistance, professional travel, or trainee support.

Scholars who engage in interdisciplinary work on individual development and learning of children and youth, and who seek to combine genetic, epigenetic, neurobiological, behavioral and social levels of analysis, are particularly encouraged to apply.

Besides providing fellows with independent and competitive funding, the program offers a wide range of non-financial benefits. Fellows are encouraged to interact with each other and make use of the Jacobs Foundation’s Conference Center Marbach Castle at Lake Constance (Germany) for short-term group retreats and workshops. Networking and alumni events will enrich the fellowships.

Fellows are selected on the basis of their research accomplishments, creativity, and potential to become leaders in the scientific community through their contributions to the field of child and youth development. International relevance of the fellow’s planned work, the alignment of planned projects with the goals of the Jacobs Foundation, and the willingness to identify with our aims and to engage actively with us will also be selection criteria.

Jacobs Early Career Research Fellowship Funding Amount: 150,000 CHF
Jacobs Advanced Research Fellowship Funding Amount: 400,000 CHF

Application deadline: The application and the recommendation letter have to be submitted until 18 March 2018, 23.59 CET.

Grantor: Craig H. Neilsen Foundation
Grant Opportunity: Research Grants
Keyword: Chronic Diseases; Neurological Disorders; Neuromuscular Disorders; Orthopaedic; Psychosocial; Research Grant

Award Amount: $400,000
Deadline: March 23, 2018

Craig H. Neilsen Foundation Psychosocial Research Studies and Demonstration Projects

http://chnfoundation.org/how-to-apply/

This funding category is intended to support substantive studies that fill important gaps in the SCI field, that open new areas of SCI psychosocial research, or that develop and evaluate interventions to address psychosocial issues after SCI. Proposed submissions in this category should facilitate, expand or improve the translation of knowledge and/or the adoption of interventions and practices that will have a positive impact for those living with SCI. Based within a psychosocial framework, PSR Studies and Demonstration Projects can range from SCI epidemiological studies to interventions that will enhance clinical treatment, rehabilitation, habilitation and/or other related quality of life subsets.

Funding for PSR Study and Demonstration Projects is for up to three years, $400,000 total costs.
Letter of Intent (LOI) Submission Due via proposalCENTRAL: March 23, 2018 5:00 PM (Eastern Time)

Grantor: Pfizer

Grant Opportunity: Medical Education Grants

Keyword: Chronic Diseases; Inflammatory Bowel Disease; Quality Improvement

Award Amount: $350,000
Deadline: March 16, 2018

Independent Grants for Learning & Change Track 2 - Call for Grant Applications Emerging Treatments and Preventative Care Strategies for Patients With Inflammatory Bowel Disease (IBD)

https://www.pfizer.com/purpose/medical-grants/process

Clinical Area: Inflammatory Bowel Disease

Specific Area of Interest for this CGA: The intent of this CGA is to encourage organizations to design educational programs to reach gastroenterologists and gastroenterology fellows, nurse
practitioners, physician assistants, and all other healthcare professionals involved in the care and treatment of adult patients with inflammatory bowel disease (IBD).

As research has progressed into the pathogenesis of the IBD spectrum, new therapeutic targets and strategies have been discovered. Additionally, research has demonstrated that IBD patient do not always receive the preventive services they need. This is particularly important for patients requiring long-term immune-suppressive therapy who are at increased risk of infections. Adherence to appropriate vaccination guidelines can help mitigate this risk, yet a number of studies have demonstrated poor compliance with vaccination guidelines.

Programs aimed at increasing awareness and understanding of emerging therapies or foster an understanding and implementation of innovative preventative care strategies in the treatment of adult patients with IBD will be considered.

Organizations responding to this CGA should recognize these and other priority knowledge gaps in mind when designing programs.

Programs with the highest likelihood of improving clinical gastroenterologists’ and gastroenterology fellows’, nurse practitioners’, physician assistants’, and all other healthcare professionals’ understanding of the current vaccination guidelines, the importance of vaccination in the care of IBD patients, and/or improving the health care team’s understanding of emerging therapies will be given the highest priority.

All activity types will be considered through this CGA, including live events, satellite symposia, workshops, online courses, print materials, and other enduring materials, including published proceedings. Efforts should be made to encourage interaction, incorporate real-world patient case discussions, and provide opportunities to extend and reinforce learning opportunities beyond the live setting.

Individual projects requesting up to $350,000 will be considered.

Grant application due date: March 16, 2018

Grantor: Pfizer
Grant Opportunity: Medical Education Grants
Keyword: Cancer; Chronic Diseases; Quality Improvement
Award Amount: $250,000
Deadline: March 15, 2018

Independent Grants for Learning & Change Track 2 - Call for Grant Applications Advances in Adjuvant Treatment in Renal Cell Carcinoma (RCC)
Clinical Area: Renal Cell Carcinoma (RCC)

Specific Area of Interest for this CGA: It is our intent to support continuing education programs that increase the awareness and understanding of Advances in Adjuvant Treatment in Renal Cell Carcinoma (RCC). Responses to this should broadly consider what happens after a patient is diagnosed with RCC and at high risk for recurrence and why an adjuvant option may be considered.

Example topics may include mechanism of disease, recurrence rates, shared-decision making, oncologist/urologist interplay, and risk stratification.

The content or format of a CME activity or its related materials must promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The target learner audiences include: Urologists, Medical Oncologists, Surgeons, Health System Pharmacists, Urological & Oncology Nurses.

All CME/CE activity types will be considered through this CGA including but not limited to; national or regional symposia, workshops, regional community series; online courses & tools, print materials and other enduring materials.

The typical grant maximum under this CGA will be up to $250,000. Larger proposals will be considered for funding if they include multiple activities such as several live events, enduring activities, and supportive materials and tools.

Grant application due date: March 15, 2018

Grantor: Craig H. Neilsen Foundation

Grant Opportunity: Pilot Grants

Keyword: Chronic Diseases; Neurological Disorders; Neuromuscular Disorders; Orthopaedic; Psychosocial; Research Grant

Award Amount: $200,000

Deadline: March 23, 2018

This funding category is intended to support Pilot studies that lay essential groundwork to inform future research, allow the PI to test the feasibility of novel methods and procedures and/or collect new data that can lead to or enhance larger-scale trials. Proposed Pilot projects should indicate
how they will establish a new investigational program or take on “risk” balanced by high potential impact.

Funding for PSR Pilot grants is for up to two years, $200,000 total costs.

Letter of Intent (LOI) Submission Due via proposalCENTRAL: March 23, 2018 5:00 PM (Eastern Time)

Grantor: National Hemophilia Foundation
Grant Opportunity: Clinical Fellowship Program
Keyword: Career Development; Chronic Diseases; Hematology; Hemophilia; Post-Doctoral Fellowship
Award Amount: $200,000
Deadline: April 4, 2018

National Hemophilia Foundation-Shire Clinical Fellowship Program

https://www.hemophilia.org/Researchers-Healthcare-Providers/Research-Grant-Programs/NHF-Shire-Clinical-Fellowship-Program

The NHF-Shire Clinical Fellowship Program, funded through the generous support of Shire, plc, is intended to increase the number of skilled clinicians committed to providing comprehensive care for individuals with bleeding disorders. The program is designed to provide licensed physicians with hands-on clinical training and prepare them for academic careers in bleeding disorders research. Mentored training takes place at highly-qualified hemophilia and/or thrombophilia treatment centers located throughout the United States. Through this program, award funding is provided to cover costs directly related to the training of physicians who show an interest in devoting their careers to the care of patients with hemophilia and other bleeding disorders.

Selections are made by an independent peer review panel and award recipients are able to receive up to $100,000/year (for up to two years).

Institutional Application Deadline: April 4, 2018
Candidate Application Deadline: April 4, 2018

Grantor: Pfizer
Grant Opportunity: Medical Education Grants
Keyword: Chronic Diseases; Geriatric; Quality Improvement
Independent Grants for Learning & Change Track 2 - Call for Grant Applications
Understanding the Importance of Calcium and Vitamin D Supplementation for Aging Men

https://www.pfizer.com/purpose/medical-grants/process

Clinical Area: Male Bone Health: Importance of Calcium & Vitamin D Supplementation

Specific Area of Interest for this CGA: It is our intent to support projects that focus on increasing the awareness about elements essential to healthy ageing in men and the components that need to be managed to maintain. Primary focus should be on bone health and Calcium and Vitamin D supplementation.

The target learner audiences include healthcare professionals with a focus on prevention and treatment of male osteoporosis, and General practitioners.

All activity types will be considered through this CGA, however, web-based education and satellite symposia has particular interest. An activity taking place alongside the American Society for Bone and Mineral Research (ASBMR) Annual Meeting in September 2018 is also of particular interest. Efforts should be made to encourage interaction, incorporate patient case discussions, and provide opportunities to extend and reinforce learning beyond the live setting.

The total available budget related to this CGA is $200,000.00 USD.

The grant amount Pfizer will be prepared to fund will depend upon the evaluation of the proposal and costs involved and will be stated clearly in the approval notification.

Grant application due date: March 19, 2018

Grantor: Pfizer
Grant Opportunity: Program Funding
Keyword: Chronic Diseases; Post-Doctoral Fellowship; Rheumatology

Rheumatology

https://www.pfizer.com/purpose/medical-grants/request-proposals
Clinical area: Rheumatology

Specific Area of Interest: It is our intent to support institutions with Rheumatology fellowship programs that have a strong focus on clinical practice, research, and education to further the understanding of Rheumatoid Arthritis and Psoriatic Arthritis.

Grants will be awarded based on the strength of the requesting organization’s ability to provide training and mentorship to the fellow, as well as the strength of the program in supporting clinical training and research.

• Individual requests for fellowship grants up to $80,000 per year for up to two years will be considered

• Funding is to be used as a salary supplement for a fellow at the recipient organization

• Funding will be awarded to the organization, which will select the recipient.

Applications due date: March 23, 2018

Grantor: Cystic Fibrosis Foundation

Grant Opportunity: Program Funding

Keyword: Chronic Diseases; Cystic Fibrosis; Genetic Disorders; Pulmonary and Respiratory; Rare or Orphan Diseases

Award Amount: $150,000+

Deadline: April 2, 2018

Cystic Fibrosis Foundation Mental Health Coordinator Award

https://proposalcentral.altum.com/GrantOpportunities.asp?GMID=14

The overall purpose of the Mental Health Coordinator Award is to promote the development of a Collaborative Care Model (CCM) at CF Centers that incorporate a system for prevention, screening for and treatment of anxiety and depression. Thus, the award is designed to facilitate implementation of the depression and anxiety guideline recommendations.

The focus of this Request for Applications (RFA) is to provide seed funding for a CF Mental Health Coordinator (MHC) to programs that have not previously received a MHC award. The MHC is expected to implement annual screening and follow-up; coordinate evidence-based treatment for depression and anxiety; develop and maintain a referral network of community-based mental health practitioners; and, serve as an educator and liaison for mental health care in CF for the CF Center, hospital or institution, community practitioners, and payers. This person will provide basic information about the common symptoms of depression and anxiety, provide follow-up for those individuals scoring in the elevated range, provide interventions to improve
patients’/parents’ coping skills, and behavioral interventions for painful medical procedures. He/she will collect data on screening scores and subsequent assessment and follow-up, provision of interventions, and their outcomes. Additionally, he/she will indicate in the patient registry on the annual form if the screening has been completed for the individual with CF.

Funding: The maximum award amount is $150,000 in direct costs plus eight percent (8%) indirect costs over three (3) years.

Application Deadline: April 2, 2018

Grantor: Craig H. Neilsen Foundation
Grant Opportunity: Pilot Grants
Keyword: Chronic Diseases; Neurological Disorders; Neuromuscular Disorders; Orthopaedic; Post-Doctoral Fellowship; Psychosocial
Award Amount: $150,000
Deadline: March 23, 2018
Craig H. Neilsen Foundation Psychosocial Research Postdoctoral Fellowships

http://chnfoundation.org/how-to-apply/

This funding is designed to encourage specialization in the field of SCI; Fellowships are intended to provide mentored training in SCI research to early-career investigators. The Fellowship Applicant (Fellow) should be mentored (or co-mentored) by an investigator experienced in SCI psychosocial research.

Funding for Fellowships is $75,000 per year, for up to two years; $150,000 total costs.
Letter of Intent (LOI) Submission Due via proposalCENTRAL: March 23, 2018 5:00 PM (Eastern Time)

Grantor: Tuberous Sclerosis Alliance
Grant Opportunity: Postdoctoral Fellowships
Keyword: Basic Science; Chronic Diseases; Genetic Disorders; Post-Doctoral Fellowship; Rare or Orphan Diseases
Award Amount: $150,000
Deadline: May 7, 2018
Tuberous Sclerosis Alliance Postdoctoral Fellowships

http://www.tsalliance.org/researchers/grants-and-funding/

Duration: up to two years (can be shorter if appropriate for the project and the trainee)

Maximum total costs of $75,000 per year ($150,000 total) inclusive of both direct and indirect costs

Postdoctoral fellowship awards may support any type of basic or translational research relevant to TSC that provides an outstanding opportunity for the trainee’s professional growth.

Letters of Intent must be submitted no later than May 7, 2018, at 11:59 p.m. US EDT.

Grantor: Tuberous Sclerosis Alliance
Grant Opportunity: Research Grants
Keyword: Basic Science; Chronic Diseases; Genetic Disorders; Rare or Orphan Diseases; Research Grant
Award Amount: $150,000
Deadline: May 7, 2018

Tuberous Sclerosis Alliance Research Grants

http://www.tsalliance.org/researchers/grants-and-funding/

Duration: up to two years (can be shorter if appropriate for the project)

Maximum total costs of $75,000 per year ($150,000 total) inclusive of both direct and indirect costs

Research plans should address one of the following four high-priority areas:

Understanding phenotypic heterogeneity in TSC, i.e., research on genetic, biologic, or environmental factors that might explain why TSC is so different from person to person

Gaining a deeper knowledge of TSC signaling pathways and the cellular consequences of TSC deficiency

Improving TSC disease models, whether cell-based, tissue-based, or animal models

Developing clinical biomarkers or patient-reported outcome measures for TSC, particularly those that assess disease burden or stratify an individual’s risk of progression or developing specific manifestations of TSC
Letters of Intent must be submitted no later than May 7, 2018, at 11:59 p.m. US EDT.

Grantors: Orphan Disease Center of the University of Pennsylvania School of Medicine and the Loulou Foundation

Grant Opportunity: Pilot Grant Program

Keyword: Chronic Diseases; Epilepsy; Genetic Disorders; Neurological Disorders; Rare or Orphan Diseases; Research Grant

Award Amount: $150,000

Deadline: March 8, 2018

Orphan Disease Center and Loulou Foundation 2018 CDKL5 Program of Excellence Pilot Grant Program

http://orphandiseasecenter.med.upenn.edu/grant-opportunities/cdkl5-program-of-excellence

The ODC and Loulou Foundation CDKL5 Pilot Grant Program provides a one-year grant for $150,000.00 (total cost) to support research related to CDKL5 Deficiency Disorder (CDD). The number of awards may vary.

We are seeking grant applications that progress the discovery or development of treatments and/or a cure for CDKL5 Deficiency. We recognize, however, that many gaps exist in the basic understanding of CDKL5 and its role in neurologic development. Therefore, basic science projects that address these gaps are welcome as long as they are tethered to the development of a potential therapy. While the RFA is broad in scope, priority will be given to grants that cover the following areas:

Novel therapeutic approaches for CDKL5 Deficiency Disorder (CDD), including but not limited to techniques in genome editing, RNA-based mechanisms, biologics, and small molecule repurposing.

Approaches to validate phenotypes in CDKL5 function or disease pathophysiology through rescue of phenotypic deficits with pharmacological or genetic / gene therapy techniques. Phenotypic reversal in rodent models will focus on the use of adult (2 months of age or older) animals. In particular, approaches are encouraged which allow the identification of individual CDKL5 protein isoforms (arising from alternative splicing, alternative promoter usage, or post-translational modifications) which can rescue these phenotypes.

Systems biology and computational modeling approaches to provide a deeper understanding of CDKL5 function, downstream effectors, signaling, protein: protein interactors, or modifiers, including regulators of CDKL5 gene expression (transcriptional, post-transcriptional/RNA processing, translational, post-translational).
Novel imaging and functional approaches to phenotyping CDD in pre-clinical models or the clinical setting. A non-exclusive list of topics that would be responsive to this RFA is listed below:

- Functional/structural MRI; diffusion tensor imaging (DTI)
- Magnetic resonance spectroscopy (MRS)
- Stimulus-induced event-related potentials: impact of CDKL5 genetic / gene therapy or pharmacological interventions on deficits in stimulus-induced event potentials (visual, auditory, or other) in CDD disease models.
- Discovery and validation of CDKL5 biomarkers and their translation to the clinical setting.

Eligibility: All individuals holding a faculty-level appointment at an academic institution or a senior scientific position at a non-profit institution or foundation are eligible to respond to this RFA.

Letter of intent deadline: March 8, 2018

Grantor: Center for SUDEP Research

Grant Opportunity: Pilot Grants

Keyword: Chronic Diseases; Epilepsy; Neurological Disorders; Research Grant

Award Amount: $80,000

Deadline: March 14, 2018

NINDS Center for SUDEP Research Pilot

http://casemed.case.edu/ctsc/funding/ninds.cfm

The Center for SUDEP Research (CSR) has been established to study Sudden Unexpected Death in Epilepsy (SUDEP). This Epilepsy Center Without Walls includes over 40 clinicians and scientists from 14 institutes across the U.S. and U.K. This five-year research initiative is supported by the National Institute of Neurological Disorders and Stroke at the National Institutes of Health (NIH) and brings together many of the leaders in the field of SUDEP research.

The CSR is composed of a multidisciplinary group of investigators with expertise in molecular biology, genetics, neuropathology, electrophysiology, brain imaging, epilepsy, respiratory physiology, cardiology, and bioinformatics. The team will be involved in nine projects that combine basic research and clinical findings with the common goal of quickly taking SUDEP lab results into the clinic.
Pilot Projects: The CSR seeks novel pilot projects that will address the goal of understanding and eliminating SUDEP. This pilot program will award grants to national and international researchers submitting innovative proposals that compliments and expands on the SUDEP research proposed in the CSR. The CSR plans to support one clinical pilot project (clinical trials will not be funded through this mechanism, but studies involving human subjects are allowed) and one basic research project. Infrastructure building applications are discouraged and applications need to have robust scientific hypotheses. Utilizing current existing CSR Cores and expertise is strongly recommended. Successful applicants will be expected to work collaboratively with the CSR investigators.

Budget: Requests may be made for up to $80,000 in total (direct+indirect) costs paid over 1 year.

Submission of application

All applications should be submitted to: http://webgrants.case.edu/
And must be received by 5:00pm EDT, Wednesday, March 14, 2018.

Grantor: Oxalosis & Hyperoxaluria Foundation

Grant Opportunity: Research Grants

Keyword: Chronic Diseases; Genetic Disorders; Kidney Disease; Rare or Orphan Disorders; Research Grant

Award Amount: $60,000

Deadline: Open

Call for Proposals: Oxalosis & Hyperoxaluria Foundation Global Registry Initiative

http://ohf.org/grants-funding/

Call for proposals to develop international collaborative patient registries and databases to identify the determinants of the clinical manifestations and prognosis of patients with primary hyperoxaluria.

As part of its wider mission to improve the understanding and treatment of primary hyperoxaluria (PH) and related calcium oxalate kidney stone diseases, the Oxalosis & Hyperoxaluria Foundation (OHF) is interested in receiving proposals from scientists and clinicians that address the issue of the influence of genetic, cultural, and environmental background on the clinical manifestations and prognosis of patients with PH. To this end, financial support will be given to international collaborative projects that develop and make use of well-defined patient cohorts covering a wide range of genetic and cultural backgrounds.

Possible questions to be addressed include, but are not limited to, 1) the influence of urinary oxalate level and other urine parameters on renal outcomes, 2) the influence of dietary intake on
Proprietary Information. For internal University of Michigan use only.

Urinary oxalate level and renal outcomes, and 3) genotype-phenotype correlations within and between PH types. In countries where no such databases exist, the OHF is willing to provide funding to help local clinicians and scientists to organize collections of PH patient information into standardized registries and databases and to make this information available for approved research projects which address the issues above. A required element of a successful response to this proposal will be a detailed data sharing plan for key data elements that are collected under this program.

Proposed timelines can be 1-2 years; however additional funds will be available for registry maintenance to sites that achieve predefined benchmarks (i.e. patient enrollment targets) in the first year. Successful proposals will benefit clinicians in treating PH patients and provide a framework for the evaluation of existing and potential new therapies.

Award Budget--- The total costs (direct and indirect) for a project awarded will not exceed $60,000 for the entire project period.

Application Deadline: Open

Grantor: ZOLL Foundation

Grant Opportunity: Research Grants

Keyword: Acute Care; Cardiovascular; Heart Attack; Pulmonary and Respiratory; Quality Improvement; Research Grant

Award Amount: $50,000

Deadlines: March 31, 2018; September 30, 2018

ZOLL Foundation Grants Program

http://www.zollfoundation.org/index.html

Newer researchers building their reputations through promising study topics could benefit from “seed” grants available from the ZOLL Foundation. Our focus is on working with budding investigators conducting research in the fields of resuscitation or acute critical care. We hope to provide those starting out a platform upon which to build their success. Whether a study aims to improve practices, prevent patient deterioration, reduce mortality and morbidity, or addresses some other aspect of enhancing care, we invite you to apply.

Approvals by the Board of Directors are oriented toward:

- early research in new therapies or techniques;
- reviews of data and information to better understand practices in the field of resuscitation and acute critical care;
educational activities combined with measurement to enhance care; and

promising start-up projects whose initial results may allow researchers to seek additional funding from other sources, allowing for continued research that will require more extensive trials or scale.

While large scale studies and trials are the gold standard for changes in resuscitation and acute critical care, "seed money" as an initial investment, or to look at the effects of new technologies or training practices, is often the nascent stimulus of later changes in practices and the development of improved technologies. The ZOLL Foundation will support these areas by awarding grants typically in the $10 - $50,000 range, rather than consider larger scale studies.

We have moved from a rolling application process to bi-annual deadlines of March 31 and September 30 starting in 2018.

Grantor: GlaxoSmithKline
Grant Opportunity: Medical Education Grant
Keyword: Quality Improvement
Award Amount: $35,000
Deadline: April 5, 2018
Call for Grant Applications: Oral Health

https://www.partnersinknowledge.com/GSKCenterforMedicalEducation/imeGrantReview/index.html

Our intent is to fund educational initiatives that are designed to close at least 1 of the following independently identified healthcare gaps; however, other independently identified healthcare gaps are also encouraged to be included:

(1) Lack of understanding of oral conditions such as acid erosion/wear, xerostomia, periodontal disease and oral conditions found in the edentulous

(2) Appropriate understanding of available treatments to improve oral health and treat disease

Our intent is to fund educational initiatives that use multi-channel platforms and reach a national or regional audience. Preference is for educational initiatives that are accredited (eg, by the APCE, ADA CERP, etc).

Educational Outcomes: Grants that are designed to measure improvements/changes in HCP knowledge (Level 3), competence (Level 4) performance (Level 5), and/or patient/community health (Level 6/7) are funding priorities.
Grant requests up to $35,000 will be considered for funding.

Grants may be submitted between March 5, 2018 and April 5, 2018, with a grant start date of June 15, 2018, or later.

Grantor: David Geffen School of Medicine at UCLA
Grant Opportunity: Research Prize
Keyword: Basic Science; Prizes
Award Amount: $25,000
Deadline: March 30, 2018

Call for Nominations: 2018 Switzer Prize

http://medschool.ucla.edu/nomination-process

The Switzer Prize honors revolutionary discoveries in basic research in the biological and biomedical sciences and celebrates recent advances with the potential to inspire transformative breakthroughs in medicine. The prize is awarded to an individual investigator whose recent work has revealed new paradigms, illuminated biological processes or pathways, or explained the origins of pathologies or diseases. The recent work must show the potential for continued outstanding contributions to the field.

Nominations are open to national and international candidates from any institution. Nominations may be made by an individual or institutions, but self-nominations are prohibited.

The Prize: The winner, to be named in Spring 2018, will receive a $25,000 honorarium. The recipient will deliver the annual Switzer Prize lecture at the David Geffen School of Medicine at UCLA in Fall 2018.

Deadline: The deadline for nominations is March 30, 2018.

Grantor: Science
Grant Opportunity: Research Prize
Keyword: Neurological Disorders; Prizes
Award Amount: $25,000
Deadline: March 15, 2018

Science & PINS Prize for Neuromodulation
The Science & PINS Prize for Neuromodulation is a highly competitive prize which honors scientists for their excellent contributions to neuromodulation research. Neuromodulation is any form of alteration of nerve activity through the delivery of physical (electrical, magnetic, optical) stimulation to targeted sites of the nervous system. Established in 2016, the prize is awarded annually for outstanding research as described in a 1,500 word essay based on research performed in the past three years.

The winner of the Science & PINS Prize for Neuromodulation is awarded US$25,000 and publication of his or her essay in Science. The Grand Prize essay and that of the Runner-up are also published on Science Online.

Next application deadline: March 15, 2018